CHEMILUMINESCENCE IMMUNOASSAY MARKET ANALYSIS

The presence of alternative techniques for immunoassays can hamper the global chemiluminescence immunoassay market growth. Technologies like fluorescence immunoassay and enzyme-linked immunosorbent assay (ELISA) are well-established alternatives to chemiluminescence immunoassay. Fluorescence immunoassay uses fluorescent probes instead of chemiluminescent substances for detection. It provides strong signals, high sensitivity, and allows detecting multiple analytes simultaneously by using different fluorescent dyes. ELISA is also a popular immunoassay technique that employs enzymes for signal generation instead of chemiluminescence. Both fluorescence and ELISA methods are faster, simpler to perform, and more cost-effective as compared to chemiluminescence immunoassay. The widespread adoption of these alternative technologies by clinical laboratories and hospitals can restrict the potential customer-base expansion of chemiluminescence immunoassay. For example, according to a 2019 report published by the World Health Organization (WHO), around 70% of clinical microbiology laboratories in low and middle-income countries mainly rely on ELISA and rapid diagnostic tests rather than chemiluminescence immunoassay for detecting infectious diseases due to their lower cost and simpler operation. The preference for alternative cost-effective techniques is significantly hampering the sales and marketing opportunities of chemiluminescence immunoassay analyzers/reagents globally.

Market Opportunities: Launch of advanced CLIA diagnostic technologies

The launch of advanced chemiluminescence immunoassay (CLIA) diagnostic technologies provide a great opportunity to drive global chemiluminescence immunoassay market growth. CLIA techniques have significantly evolved in recent years to offer higher sensitivity, wider detection range, faster turn-around times and improved automation. Some of the key advanced CLIA technologies that are gaining traction include enhanced chemiluminescence immunoassay (ECLIA), nano-immune technology and microfluidic immunoassay systems. ECLIA systems utilize advanced signal amplification methods to enable detection of smaller concentrations of target analytes with high precision. This enhanced sensitivity of ECLIA allows detection of biomarkers at early disease stages, facilitating early diagnosis and treatment. Nano-immune technology employs the use of nanomaterials like quantum dots and gold nanoparticles in CLIA. The nanomaterial tags offer increased stability and brightness of chemiluminescence signals. This improves assay sensitivity for low abundance analytes. Microfluidic CLIA systems miniaturize the analytical process on a single microchip utilizing only minute volumes of samples and reagents. The higher surface area to volume ratio allows for rapid reaction kinetics and analysis of multiple samples on the same chip in an automated, high-throughput and cost-effective manner.